Materials inventory for the four research files
A cross-reference for the things accompanying the peptide: what they change in an experiment, and which clinical questions remain open.
Carriers, barriers and combinations
There is no useful overall ranking of these compounds. They were studied for different purposes. The comparisons that interest me run across the workbench: albumin serving as a carrier, copper bound to a short chain, a skin layer restricting passage, another active ingredient sharing a trial result.
| Research file | Accompanying material | Measurement to retain |
|---|---|---|
| CJC-1295 DAC | Albumin, bound through the DAC attachment | Hormone activity prolonged in early studies; long-term health outcomes remain unresolved. |
| GHK-Cu | Copper, the carrying mixture and the skin barrier | Copper crossing and remaining in prepared skin; visible skin changes require human testing. |
| Semaglutide | Reversible albumin binding; oral absorption-enhancing ingredient | Weight change in STEP 1; heart and kidney trials concern their specified patient groups. |
| Thymosin Alpha-1 | An intact peptide within a broader course of clinical care | No clear survival benefit in TESTS; immune measurements cannot settle a survival question. |
Two ways of recruiting albumin
CJC-1295 DAC makes a covalent attachment. Semaglutide binds reversibly. Both designs increase the time a peptide can act, as described in the CJC-1295 work and semaglutide pharmacology review.
Their clinical records separate sharply after that shared chemical theme. CJC-1295’s early human studies established changes in GH and IGF-1. Semaglutide trials measured average weight change and cardiovascular or kidney outcomes. My respect for albumin’s usefulness extends to both designs; my confidence about clinical benefit follows the actual trials.
Attribution in a mixture
The GHK-containing hair trial is a particularly useful entry in this inventory. A result measured after two active ingredients were given together supports that combination. The study leaves each ingredient’s individual contribution open.
Likewise, the GHK-Cu delivery review treats the surrounding formulation as something that can change performance. A cell study skips the outer skin barrier. A penetration experiment includes a prepared version of it. A clinical study tests a preparation in living people. Substituting one of those settings for another can change the claim while leaving the peptide name untouched.
The individual essays hold the fuller accounts: CJC-1295, GHK-Cu, semaglutide and Thymosin Alpha-1.